Document Detail


Hyaluronidase therapy for acute myocardial infarction: results of a randomized, blinded, multicenter trial. MILIS Study Group.
MedLine Citation:
PMID:  2872794     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A randomized, double-blind, multicenter study was conducted of the value of hyaluronidase therapy for acute myocardial infarction (AMI). Patients were eligible for enrollment if they were less than 76 years old, had at least 30 minutes of pain typical of myocardial ischemia and had electrocardiographic changes suggestive of acute ischemia or evolving infarction. A total of 851 patients were randomly assigned to hyaluronidase (500 National Formulary units/kg intravenously every 6 hours for 48 hours) or placebo therapy with a mean of 9.4 +/- 0.1 hours after the onset of pain. There were no significant differences between the hyaluronidase- and placebo-treated patients in incidence of AMI (86 vs 88%), creatine kinase-MB infarct size index (14.6 +/- 0.8 vs 15.1 +/- 0.7 CK-MB-gEq/m2), change in total R wave from time 0 to 72 hours for anterior transmural ischemia or infarction (-34 +/- 7 vs -35 +/- 8 mV), infarct size determined by pyrophosphate scintigrams (27 +/- 1 vs 27 +/- 1 cm2), change in left ventricular ejection fraction from day 0 to day 10 (+ 2.4 +/- 0.7 vs + 1.2 +/- 0.7%) or cumulative proportion surviving 4 years (0.70 +/- 0.03 vs 0.68 +/- 0.03). These findings indicate there is no overall benefit from administration of hyaluronidase more than 9 hours after the onset of AMI, but do not exclude the possibility that such therapy could be of value if given earlier, or if given to a subgroup of patients with sufficient residual flow to the area of AMI.
Authors:
-
Related Documents :
3878284 - The declining trend in the incidence of acute myocardial infarction in finland. the res...
17485154 - Do not go breaking your heart: do economic upturns really increase heart attack mortality?
1955684 - Evaluation of a mobile coronary care unit protocol in patients with acute onset chest p...
11448404 - Age and the utilization of cardiac catheterization following uncomplicated first acute ...
9170134 - Inappropriate management of self-terminating ventricular arrhythmias by implantable car...
23940444 - Effect of metoprolol on myocardial apoptosis and caspase-9 activation after coronary mi...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The American journal of cardiology     Volume:  57     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1986 Jun 
Date Detail:
Created Date:  1986-06-27     Completed Date:  1986-06-27     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1236-43     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Clinical Trials as Topic
Double-Blind Method
Female
Humans
Hyaluronoglucosaminidase / therapeutic use*
Male
Middle Aged
Myocardial Infarction / diagnosis,  drug therapy*
Random Allocation
Grant Support
ID/Acronym/Agency:
N01-HV-7-2940/HV/NHLBI NIH HHS; N01-HV-7-2941/HV/NHLBI NIH HHS; N01-HV-7-2942/HV/NHLBI NIH HHS
Chemical
Reg. No./Substance:
EC 3.2.1.35/Hyaluronoglucosaminidase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Neurohumoral consequences of vasodilator therapy with hydralazine and nifedipine in severe congestiv...
Next Document:  Influence of beta blockade and intrinsic sympathomimetic activity on hemodynamics, inotropy and resp...